Strides Arcolab mulls to put its injectable medicine block on sale: Reports

10 Aug 2012 Evaluate

Global pharmaceutical company, Strides Arcolab is mulling to part ways with its injectable medicines unit called Agila Specialties, which might be valued at more than Stride's current market value of $800 million, as mentioned in few media reports. Company’s Agila unit manufactures injectable medicines. The unit so far has a decent track record of winning approvals for its new products, it has supply deals with GlaxoSmithKline and Novartis.

Recently, Strides Arcolab’s wholly owned subsidiary Onco Therapies had received final ANDA approval for Oxaliplatin Injection 50mg/10mL and 100mg/20mL. The company had received tentative approval from USFDA in November 2011 based on a Para III filing. This approval was later converted to a Para IV filing based on which USFDA has now granted final approval.

Strides Arcolab is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures wide range of IP-lead niche pharmaceutical products with an emphasis on sterile injectables.

Strides Pharma Scien Share Price

954.85 13.90 (1.48%)
03-Jul-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1531.05
Dr. Reddys Lab 6428.05
Cipla 1482.30
Zydus Lifesciences 1093.45
Lupin 1637.60
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.